公开(公告)号：US20070275006A1

公开(公告)日：2007-11-29

申请号：US11683975

申请日：2007-03-08

申请人： Anamika Khajuria ,  Amit Gupta ,  Singh Surjeet ,  Fayaz Malik ,  Jaswant Singh ,  Kasturi Lal Bedi ,  Krishan Suri ,  Naresh Satti ,  Om Suri ,  Ghulam Qazi ,  Vellimedu Srinivas ,  Krishna Ella

发明人： Anamika Khajuria ,  Amit Gupta ,  Singh Surjeet ,  Fayaz Malik ,  Jaswant Singh ,  Kasturi Lal Bedi ,  Krishan Suri ,  Naresh Satti ,  Om Suri ,  Ghulam Qazi ,  Vellimedu Srinivas ,  Krishna Ella

IPC分类号： A61K45/00 ,  A61K39/385 ,  A61K47/00

CPC分类号： C07H17/04 ,  A61K39/0275 ,  A61K39/12 ,  A61K39/292 ,  A61K39/39 ,  A61K2039/55505 ,  A61K2039/5555 ,  A61K2039/55566 ,  A61K2039/55583 ,  A61K2039/57 ,  C12N2730/10134 ,  Y02A50/484

摘要： The present invention relates to an adjuvants, particularly to the use of a well-characterized plant based iridoid glycoside adjuvant from plant Picrorhiza kurroa, acting as an adjuvant against T-dependent antigen and specifically against HBsAg and typhoid antigens. The present invention also relates to the method of producing the iridoid glycoside adjuvant and the products utilizing such adjuvants for induction of cellular immunity. The adjuvants may be used alone or with specific antigens. The two antigens used in the study represents HBsAg, a recombinant antigen expressed in Pichia pastoris, and typhoid Vi polysaccharide purified from Salmonella typhi broth. These antigens are studied for their immunogenicity with the adjuvant iridoid glycoside adjuvant

摘要翻译： 本发明涉及一种佐剂，特别是涉及使用来自植物Pic草的充分表征的植物性环烯醚萜糖苷佐剂的佐剂，其作为对T依赖性抗原的佐剂，特异性地抗HBsAg和伤寒抗原。 本发明还涉及生产环烯醚萜苷佐剂的方法和利用这些佐剂诱导细胞免疫的产物。 佐剂可以单独使用或与特定抗原一起使用。 研究中使用的两种抗原代表HBsAg，一种在巴斯德毕赤酵母中表达的重组抗原，以及从伤寒沙门氏菌培养液中纯化的伤寒Vi多糖。 研究这些抗原与佐剂环烯醚萜苷佐剂的免疫原性

公开(公告)号：US20090298938A1

公开(公告)日：2009-12-03

申请号：US12401337

申请日：2009-03-10

申请人： Ghulam Nabi Qazi ,  Subhash Chandra Taneja ,  Jaswant Singh ,  Ajit Kumar Saxena ,  Vijay Kumar Sethi ,  Bhahwal Ali Shah ,  Bal Krishan Kapahi ,  Samar Singh Andotra ,  Ajay Kumar ,  Shashi Bhushan ,  Fayaz Malik ,  Dilip Manikrao Mondhe ,  Shanmugavel Muthiah ,  Surjeet Singh ,  Monika Verma ,  Shashank Kumar Singh

发明人： Ghulam Nabi Qazi ,  Subhash Chandra Taneja ,  Jaswant Singh ,  Ajit Kumar Saxena ,  Vijay Kumar Sethi ,  Bhahwal Ali Shah ,  Bal Krishan Kapahi ,  Samar Singh Andotra ,  Ajay Kumar ,  Shashi Bhushan ,  Fayaz Malik ,  Dilip Manikrao Mondhe ,  Shanmugavel Muthiah ,  Surjeet Singh ,  Monika Verma ,  Shashank Kumar Singh

IPC分类号： A61K31/19 ,  C07C62/30

CPC分类号： A61K31/19

摘要： The present invention relates to use of compounds of general formula 1 for anticancerous activity, wherein the said compound being derived semi-synthetically from natural triterpenoic acids known as boswellic acids by the induction of apoptosis thereof cytotoxicity and anti-cancer activity displayed by semi-synthetic analogues of natural triterpenes, known as Boswellic acids. These compounds may be used for the treatment of cancer, alone or in combination with pharmaceutically acceptable or other carriers, displaying cytotoxicity and anti-cancer activity for colon, prostrate, liver, breast, central nervous system (CNS), leukemia and malignancy of other tissues, including ascites and solid tumors. The cancer cell death is mediated by induction of apoptosis and inhibition of cell proliferation at specific doses.

摘要翻译： 本发明涉及通式1的化合物用于抗癌活性的用途，其中所述化合物通过诱导其细胞凋亡的细胞毒性和半合成显示的抗癌活性而被天然三萜烯酸被称为保乳酸半合成衍生 天然三萜类似物，称为乳香酸。 这些化合物可以单独使用或与药学上可接受的或其它载体组合用于治疗癌症，显示对结肠，前列腺癌，肝癌，乳腺癌，中枢神经系统（CNS），白血病和其他恶性肿瘤的细胞毒性和抗癌活性 组织，包括腹水和实体瘤。 癌细胞死亡是通过细胞凋亡的诱导和特定剂量的细胞增殖抑制来介导的。